Search

everythinglearnresearchcommunity

for

Search:↓

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.

VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

Tofacitinib may effectively regrow hair in alopecia totalis patients.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Betulinic acid can help treat hepatitis C by stopping virus replication.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

3D imaging effectively tracks skin changes in vitiligo treatment.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.

Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.

An HIV patient's complete hair loss was reversed after switching from lopinavir/ritonavir to nelfinavir.